About the group
Mechanisms that underlie treatment resistance, such as tumour heterogeneity, tumour-stroma interactions, and metabolic rewiring are investigated in human tumour tissues, human 2D- and 3D-cell cultures, and human serum samples. . The following methods are being used: histomorphology, immunohistochemistry, proteomics, metabolomics, lipidomics, digital spatial profiling, and mass cytometry.
The research group is part of the Norwegian Cancer Society´s National Group of Expertise on Pancreatic Cancer Research.
Projects
- Metabolomics, lipidomics and chemosensitivity. Funded by the Norwegian Cancer Society.
- AI for improved management of pancreatic cancer patients: the PANCAIM project (Pancreatic cancer Artificial Intelligence for genomics and personal-ised Medicine).
Funded by ERC ((EU Horizon 2020). - Improved assessment of treatment effect in pancreatic cancer: the International Study Group of Pancreatic Pathologists (ISGPP).
- Morphological (intra-)tumour heterogeneity and its correlation with structural and functional diversity in pancreatic cancer. Funded by The Norwegian Cancer Society.
- Correlation of serum and tissue metabolomics with the effect of neoadjuvant chemotherapy. Funded by the Norwegian Cancer Society.
- Correlation of PET-CT (FDG and FAPI) with tumour tissue metabolism and FAP-expression in pancreatic cancer: the NorPACT-3 study (PI: KJ Labori). Funded by Helse Sør-Øst, Den Norske Patologforening, and Fondsstiftelsen.
- Development of chemoresistance in 2D- and 3D- cell culture models for pancreatic cancer. Funded by Bruuns legat and FRIMED.
- Characterisation of residual cancer following neoadjuvant therapy for pancreatic cancer. Funded by Helse Sør-Øst.
- Spatial and single-cell transcriptomics analysis of lymph node metastasis in oancreatic cancer.
- Metabolic rewiring and chemoresistance in pancreatic cancer. Funded by Helse Sør-Øst, Family Blix Endowment, and Fondsstiftelsen at Oslo University Hospital.
- Characterisation of the genomic landscape and morphological phenotype of pancreatic cancer in genetically predisposed individuals: the PREPAIRD study (Personalized suRveillance for Early detection and prevention of Pan-creatic cAncer in high Risk inDividuals; PI: EM Grindedal, Oslo University Hospital). Funded by Helse Sør-Øst.
- Ex vivo culturing of precision-cut human pancreatic cancer slices.
Collaboration
National
- The Norwegian Cancer Society´s National Group of Expertise on Pancreatic Cancer Research
- Knut Jørgen Labori, Department of HPB Surgery, Oslo University Hospital
- Elin M. Grindedal, Department of Medical Genetics, Oslo University Hospital
- Biswajyoti Sahu, Norwegian Center of Molecular Medicine (NCMM), University of Oslo
- Coen Campsteijn, Institute for Basic Medical Sciences, University of Oslo
- Anders Molven, Department of Clinical Medicine, Biomedicine, and Clinical Research, University of Bergen
International
- Nuria Malats, Spanish National Cancer Research Centre (CNIO), Spain
- David Chang, University of Glasgow, United Kingdom
- Marc Besselink, Amsterdam Medical Center, The Netherlands
- Maria Ulvmar, University of Uppsala, Sweden
